Amgen Advances MariTide Obesity Study with Ongoing Clinical Trial
Amgen Inc (AMGN) is making progress in its ongoing clinical study of MariTide, a potential treatment for obesity and diabetes. The MARITIME-2-EXTENSION Phase 3 trial aims to determine whether benefits on weight and blood sugar can be sustained over time while maintaining safety and tolerability.
The study uses a randomized, parallel design, with patients assigned by chance to different groups receiving either MariTide or placebo injections. The doses are varied, with some patients receiving the drug every 4 weeks or every 8 weeks.
The extension phase of the trial was first submitted on June 29, 2026, and the latest update was filed on August 21, 2026. While the primary and final completion dates remain pending, the ongoing progress may support sentiment toward AMGN as a long-term growth story.